{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "ESTRADIOL VALERATE",
      "indication": "INDICATIONS AND USAGE Estradiol Valerate Injection is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).",
      "manufacturer": "American Regent, Inc.",
      "splSetId": "2984bce2-89bf-4768-a1ca-ccf03b1197be"
    },
    {
      "brand": "Estradiol Valerate",
      "indication": "INDICATIONS AND USAGE Estradiol Valerate Injection, USP is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).",
      "manufacturer": "Hikma Pharmaceuticals USA Inc.",
      "splSetId": "66f40ab0-4432-4e85-b709-a0bc076868c6"
    },
    {
      "brand": "ESTRADIOL VALERATE",
      "indication": "INDICATIONS AND USAGE Estradiol Valerate Injection is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).",
      "manufacturer": "Perrigo Company",
      "splSetId": "c5f32941-3427-4a38-bc3d-38337b41d9d3"
    },
    {
      "brand": "Delestrogen",
      "indication": "INDICATIONS AND USAGE DELESTROGEN (estradiol valerate injection, USP) is indicated in the: 1.Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2.Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3.Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4.Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).",
      "manufacturer": "Par Pharmaceutical, Inc.",
      "splSetId": "e8f94df9-0692-4462-a7f0-fe019a0a3f07"
    }
  ],
  "id": "Estradiol_Valerate",
  "nciThesaurus": {
    "casRegistry": "979-32-8",
    "chebiId": "",
    "chemicalFormula": "C23H32O3",
    "definition": "The parenterally-administered synthetic valerate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females.  As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors.  This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability.",
    "fdaUniiCode": "OKG364O896",
    "identifier": "C1090",
    "preferredName": "Estradiol Valerate",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C478"
    ],
    "synonyms": [
      "Delestrogen",
      "ESTRADIOL VALERATE",
      "Estradiol Valerate"
    ]
  }
}